Japan has begun nationwide over-the-counter sales of the morning-after pill, giving women of all ages faster access to emergency contraception. The rollout started Monday at roughly 7,000 pharmacies and drugstores, removing previous age restrictions and eliminating the need for parental consent. Health officials said the policy aims to improve timely contraception access and reduce unintended pregnancies.
The approved emergency contraceptive, NorLevo, works best when taken within 72 hours after unprotected sex. Pharmacists administer the pill on site to ensure correct usage and guide patients through the process. In addition, only pharmacies that provide private consultation spaces and coordinate with nearby obstetricians may sell the medication. The Ministry of Health, Labor and Welfare published a list of eligible stores, including information on staff numbers and gender, to help women find suitable locations.
The morning-after pill costs 7,480 yen, about $50 per dose, and pharmacies do not sell it online. Only the individual needing the medication may purchase it, and men or other third parties cannot buy it. Pharmacists follow a checklist to confirm eligibility. Furthermore, they advise women to take a pregnancy test or visit a gynecologist three weeks after use.
At a drugstore near Tokyo’s JR Shinjuku Station, boxes of the contraceptive and informational pamphlets were on display for customers. The store’s 20 pharmacists completed the required training, which allows them to sell the pill even during late-night hours. Private consultation spaces ensure that women can discuss concerns confidentially. “We have female pharmacists and aim to respect a woman’s privacy and feelings,” said Yusuke Matono, the pharmacist-in-charge. “Please don’t keep your worries to yourself. Come in for a consultation as soon as possible.”
Pharmacies also encourage women under 16 or those making repeated purchases in a short period to see a healthcare provider. Staff can connect customers to local support organizations if they suspect sexual assault or abuse. Japan first trialed over-the-counter sales for women aged 16 and older at selected drugstores in November 2023. Positive results from the trial informed the nationwide rollout.
Healthcare experts welcomed the policy, noting that delays in obtaining emergency contraception previously increased unintended pregnancy risks. In addition, analysts said the policy strengthens reproductive autonomy and supports gender equality in Japan’s healthcare system. Officials plan to monitor usage trends, safety outcomes, and consultation results to guide future adjustments. Meanwhile, pharmacies continue to train staff and maintain private consultation areas. Overall, the morning-after pill is expected to expand timely contraceptive access and improve women’s health nationwide.
